252 related articles for article (PubMed ID: 28544032)
1. Prevalence of diabetes mellitus in Chinese children with thalassaemia major.
Liang Y; Bajoria R; Jiang Y; Su H; Pan H; Xia N; Chatterjee R; Lai Y
Trop Med Int Health; 2017 Jun; 22(6):716-724. PubMed ID: 28544032
[TBL] [Abstract][Full Text] [Related]
2. Association of iron overload and oxidative stress with insulin resistance in transfusion-dependent beta-thalassemia major and beta-thalassemia/HbE patients.
Tangvarasittichai S; Pimanprom A; Choowet A; Tangvarasittichai O
Clin Lab; 2013; 59(7-8):861-8. PubMed ID: 24133917
[TBL] [Abstract][Full Text] [Related]
3. Glucose Homeostasis and Effect of Chelation on β Cell Function in Children With β-Thalassemia Major.
Gomber S; Dabas A; Bagmar S; Madhu SV
J Pediatr Hematol Oncol; 2018 Jan; 40(1):56-59. PubMed ID: 29200160
[TBL] [Abstract][Full Text] [Related]
4. Indicators of glucose dysregulation and the relationship with iron overload in Chinese children with beta thalassemia major.
Zhang L; Meng Z; Jiang Z; Liu Z; Hou L; Cai G; Ou H; Huang S; Song Q; Fang J; Liang L
Pediatr Diabetes; 2022 Aug; 23(5):562-568. PubMed ID: 34453777
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the influence of iron overload in glucose metabolism in thalassemia major patients].
Liang LY; Lao WQ; Meng Z; Zhang LN; Hou LL; Ou H; Liu ZL; He ZW; Luo XY; Fang JP
Zhonghua Er Ke Za Zhi; 2017 Jun; 55(6):419-422. PubMed ID: 28592008
[No Abstract] [Full Text] [Related]
6. The impact of genotype on endocrine complications in thalassaemia major.
Skordis N; Michaelidou M; Savva SC; Ioannou Y; Rousounides A; Kleanthous M; Skordos G; Christou S
Eur J Haematol; 2006 Aug; 77(2):150-6. PubMed ID: 16800840
[TBL] [Abstract][Full Text] [Related]
7. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
8. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major.
Farmaki K; Tzoumari I; Pappa C; Chouliaras G; Berdoukas V
Br J Haematol; 2010 Feb; 148(3):466-75. PubMed ID: 19912219
[TBL] [Abstract][Full Text] [Related]
9. Diabetes mellitus in children suffering from beta-thalassaemia.
el-Hazmi MA; al-Swailem A; al-Fawaz I; Warsey AS; al-Swailem A
J Trop Pediatr; 1994 Oct; 40(5):261-6. PubMed ID: 7807619
[TBL] [Abstract][Full Text] [Related]
10. Prevention of Iron Overload and Long Term Maintenance of Normal Iron Stores in Thalassaemia Major Patients using Deferiprone or Deferiprone Deferoxamine Combination.
Kolnagou A; Kontoghiorghe CN; Kontoghiorghes GJ
Drug Res (Stuttg); 2017 Jul; 67(7):404-411. PubMed ID: 28320041
[TBL] [Abstract][Full Text] [Related]
11. Reduced insulin secretion in normoglycaemic patients with beta-thalassaemia major.
Angelopoulos NG; Zervas A; Livadas S; Adamopoulos I; Giannopoulos D; Goula A; Tolis G
Diabet Med; 2006 Dec; 23(12):1327-31. PubMed ID: 17116183
[TBL] [Abstract][Full Text] [Related]
12. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
Sharma R; Seth A; Chandra J; Gohain S; Kapoor S; Singh P; Pemde H
Paediatr Int Child Health; 2016 Feb; 36(1):22-7. PubMed ID: 25311879
[TBL] [Abstract][Full Text] [Related]
13. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
Gao HY; Li Q; Chen JJ; Chen GF; Li CG
Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre.
Belhoul KM; Bakir ML; Kadhim AM; Dewedar HE; Eldin MS; Alkhaja FA
Ann Saudi Med; 2013; 33(1):18-21. PubMed ID: 23458935
[TBL] [Abstract][Full Text] [Related]
15. Iron overload and glucose metabolism in subjects with β-thalassaemia major: an overview.
De Sanctis V; Soliman A; Yassin M
Curr Diabetes Rev; 2013 Jul; 9(4):332-41. PubMed ID: 23687960
[TBL] [Abstract][Full Text] [Related]
16. Insulin resistance and beta cell function in chronically transfused patients of thalassemia major.
Suvarna J; Ingle H; Deshmukh CT
Indian Pediatr; 2006 May; 43(5):393-400. PubMed ID: 16735760
[TBL] [Abstract][Full Text] [Related]
17. Cost-utility analysis of deferiprone for the treatment of β-thalassaemia patients with chronic iron overload: a UK perspective.
Bentley A; Gillard S; Spino M; Connelly J; Tricta F
Pharmacoeconomics; 2013 Sep; 31(9):807-22. PubMed ID: 23868464
[TBL] [Abstract][Full Text] [Related]
18. Effect of enhanced iron chelation therapy on glucose metabolism in patients with beta-thalassaemia major.
Farmaki K; Angelopoulos N; Anagnostopoulos G; Gotsis E; Rombopoulos G; Tolis G
Br J Haematol; 2006 Aug; 134(4):438-44. PubMed ID: 16822284
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Poggi M; Sorrentino F; Pugliese P; Smacchia MP; Daniele C; Equitani F; Terlizzi F; Guitarrini MR; Monti S; Maffei L; Losardo A; Pasin M; Toscano V
Ann Hematol; 2016 Apr; 95(5):757-63. PubMed ID: 26957357
[TBL] [Abstract][Full Text] [Related]
20. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
